Addressing Pluvicto supply issues: Czernin and Calais comment on potential solutions to insufficient supply and slowed access to 177Lu-PSMA-617 and preview a related editorial in this issue of JNM.
Page 343
Discussions with leaders: Ramsey Badawi talks with Hélène Langevin, director of the National Center for Complementary and Integrative Health, about her career-long perspective on medical treatment for the “whole patient.”
Page 344
“Last mile” for radioligand therapy: Pomykala and colleagues look at elements required to translate newly approved nuclear theranostics into routine clinical use, including the challenges of supply chain and distribution logistics.
Page 347
177Lu-PSMA in prostate cancer: Ravi and colleagues describe the process of clinical implementation of 177Lu-PSMA-617 at a major academic center, highlighting successes and hurdles, including referrals, supply issues, and patient selection.
Page 349
ER-targeted 18F-FES PET AUC: Ulaner and colleagues from an SNMMI-convened expert work group provide a brief summary of recently published appropriate use criteria for 18F-FES PET detection of estrogen receptor–positive breast cancer, including clinical scenarios.
Page 351
PET/CT or CE-CT in breast cancer: Vogsen and colleagues compare contrast-enhanced CT and 18F-FDG PET/CT for response monitoring in metastatic breast cancer using standardized response evaluation criteria, focusing on early detection of progressive disease.
Page 355
PET/CT negative predictive value: Subramaniam and colleagues report on the negative predictive value of a 12- to 14-wk posttreatment PET/CT for 2-y progression-free survival and locoregional control in patients with p16-positive locoregionally advanced oropharyngeal cancer.
Page 362
68Ga-FAPI PET and COVID-19 pitfalls: Demmert and colleagues assess 18F-FDG and 68Ga-FAPI-46 PET/CT tumor staging in a series of patients after COVID vaccination and discuss the potential of FAPI to avoid confounding postvaccination findings and provide superior tumor localization.
Page 368
PSMA targeting in salivary gland tumors: Civan and colleagues analyze the diagnostic performance of PSMA PET/CT and the dosimetry, efficacy, and safety of 177Lu-PSMA-617 radioligand therapy in salivary gland malignancies.
Page 372
PSMA vs. GRP-R PET/CT in prostate cancer: Schollhammer and colleagues describe a prospective head-to-head comparison of PSMA- and gastrin-releasing peptide receptor–targeted imaging at initial prostate cancer staging to understand how these can be used or combined in clinical practice.
Page 379
68Ga-FAP-2286 in various cancers: Pang and colleagues assess the diagnostic accuracy of 68Ga-FAP-2286, compared with 18F-FDG and 68Ga-FAPI-46, to detect primary and metastatic lesions in patients with various types of cancer.
Page 386
Predicting IBLs on PSMA PET/CT: Phelps and colleagues define variables that predict whether indeterminate bone lesions in patients with high-risk primary or biochemically recurrent prostate cancer are likely malignant or benign using features on 18F-DCFPyL PET/CT.
Page 395
177Lu-PSMA-I&T for mCRPC: Karimzadeh and colleagues detail prostate-specific antigen response and progression-free and overall survival in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-I&T and identify clinical and imaging prognostic factors.
Page 402
SPECT and 177Lu-PSMA response: John and colleagues evaluate changes in 177Lu-PSMA SPECT/CT quantitative parameters to monitor 177Lu-PSMA treatment response in men with progressive metastatic castration-resistant prostate cancer.
Page 410
Vessel wall total-body PET: Derlin and colleagues use ultrasensitive, extended-field-of-view total-body PET to explore biologic hallmarks of previously difficult-to-evaluate low-signal cardiac vessel wall pathology and crosstalk with other organs.
Page 416
PET and neutrophil elastase: Puuvuori and colleagues assess the novel neutrophil elastase inhibitor 11C-GW457427 in a pig model of acute respiratory distress syndrome, for PET detection and quantification of neutrophil activity in the lungs.
Page 423
68Ga-DOTA CSF PET: Evangelou and colleagues evaluate 68Ga-DOTA PET imaging of the cerebrospinal fluid space as a state-of-the-art approach to radionuclide cisternography in patients with suspected intracranial hypotension resulting from spinal CSF leaks.
Page 430
Plasma pTau181 vs. tau PET: Coomans and colleagues compare plasma tau phosphorylated at threonine-181 PET and tau PET in participants along the Alzheimer disease continuum, including evaluation of staging and progression.
Page 437
Visual interpretation of 18F-MK-6240: Seibyl and colleagues describe development of a visual assessment method for 18F-MK-6240 PET that provides both an overall assessment of brain tauopathy and regional characterization of abnormal tau deposition.
Page 444
Age and off-target retention of [18F]MK6240: Tissot and colleagues look at common reference region estimates in the cerebellum over time and evaluate the effects of age-related and off-target retention on longitudinal PET quantification of [18F]MK6240 in target regions.
Page 452
Tau PET tracers in CTE: Varlow and Vasdev conduct a head-to-head in vitro evaluation of 5 tau PET radiotracers in subjects pathologically diagnosed with chronic traumatic encephalopathy.
Page 460
MDMA and neurovascular uncoupling: Ionescu and colleagues delineate the acute effects of 3,4-methylenedioxymethamphetamine using simultaneous PET/fMRI in rats, with a goal of identifying more robust measures for pharmacologic research.
Page 466
AI-based SPECT attenuation correction: Shanbhag and colleagues develop and validate a deep-learning model to generate simulated attenuation correction myocardial perfusion images directly from non-corrected SPECT, without the need for CT.
Page 472
Lensless radiomicroscope: Klein and colleagues describe development of the lensless radiomicroscope, a new imaging modality, for in vitro cellular-resolution imaging of β- and α-emitting radionuclides.
Page 479
Adverse events after extravasation: Parihar and colleagues study the occurrence of short- and long-term clinical adverse events in patients after 99mTc-methylene diphosphonate whole-body bone scintigraphy with reported radiopharmaceutical extravasation.
Page 485
Perspective on diagnostic RPE: van der Pol and Mottaghy comment on radiopharmaceutical extravasation and a related article in this issue of JNM.
Page 491
Multiregion mouse kidney model: Vargas and colleagues describe development of a multiregion model of a mouse kidney based on high-resolution MRI data, with utility in calculating reference dose factors for specific mouse kidney tissues.
Page 493
Progression or response: Parihar and colleagues offer a case study in a patient with responding Hodgkin lymphoma and new liver lesions on 18F-FDG PET/CT.
Page 500
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.